AIM一次整理4篇文章，高劑量PPI沒有好處，PPI和hip fracture看來無關，會增加CDI

Proton-Pump Inhibitor Dosing and Negative Consequences

Four studies about the effects of PPI therapy

The May 10, 2010, issue of Archives of Internal Medicine included four articles about proton-pump inhibitors (PPIs). Investigators evaluated use versus nonuse and higher versus lower doses for various outcomes.

Researchers conducted a meta-analysis of seven randomized trials for bleeding peptic ulcers after endoscopic treatment in which high-dose PPIs (80-mg bolus, followed by 8 mg/hour continuous infusion for 72 hours) were compared with lower-dose PPIs. No 30-day benefit for high doses was found on rate of rebleeding, need for surgical intervention, or mortality.

Investigators from the Women's Health Initiative followed more than 130,000 women without histories of hip fractures for a mean 7.8 years. In multivariate analysis, risk for hip fracture was not higher among PPI users than among nonusers, but risk for spine fractures, forearm or wrist fractures, and total fractures was significantly higher among users. Use of PPIs was associated with marginally lower bone-mineral density at the hip but not at other sites.

In a retrospective study of more than 1100 patients with Clostridium difficile infection (CDI), recurrence was significantly more common among individuals who had received PPIs than among those who had not (25% vs. 18%); 42% of these patients had received PPIs within 14 days of CDI diagnosis. A second research group evaluated more than 100,000 discharges during 5 years to determine the association between level of acid suppression (no acid suppression, daily histamine-2 receptor antagonists, daily PPI therapy, or more-than-once-daily PPI therapy) and risk for developing nosocomial CDI. Incidence of nosocomial CDI ranged from a low of 0.3% among individuals without acid-suppression exposure to 1.4% among those who received more-than-daily PPI therapy. The association remained after adjustment for confounders.

Comment: These results remind us that high-dose PPIs might not provide additional benefit relative to lower-dose PPIs for patients with bleeding peptic ulcers and that high-dose PPI use among other patient populations could have negative consequences for bone health and C. difficile infections. An editorialist notes that more than 113 million prescriptions are written each year for PPIs and that they account for more than $13 billion in sales in the U.S. PPIs have clear clinical indications; however, they are overprescribed and likely have unintended negative consequences.

— Jamaluddin Moloo, MD, MPH

Published in Journal Watch General Medicine June 8, 2010

留言

張貼留言

這個網誌中的熱門文章

即便是用IGRA, 有時也要等大於三個月才能決定TB contact

圖片
接觸TB後，TST大抵上2-12週轉陽，IGRA大抵上6-10週，但IGRA可以長到3個月以上 TB Tests Can Have a Lengthy Window Period Two studies suggest that interferon- release assay conversion sometimes occurs more than 3 months after exposure to active tuberculosis. Increasingly, interferon- release assays (IGRAs) are being used for diagnosing latent tuberculosis (TB). Although the tuberculin skin test (TST) traditionally used for this purpose converts to positive within 2 to 12 weeks after an individual is exposed to someone with active TB, the interval for IGRA conversion has remained unclear. Current guidelines recommend repeating an initially negative IGRA after 6 to 10 weeks, but this recommendation is not based on controlled studies. Two recent investigations address this issue. Anibarro and colleagues conducted a longitudinal prospective analysis among contacts of TB patients in Spain. The 152 contacts received a TST and an IGRA at first visit; for individuals with negative or conflicting results, t
閱讀完整內容

白宮為了掌控醫療費用，傾向大型醫療，個體戶勢必受挫

所以一旦政府介入，中外醫療提供者都傾向大型化…… independent practice -> dreaming 診所評鑑??應該擋住! http://www.medscape.com/viewarticle/727420 Physicians Say White House Should Not Write Off Small Practices August 24, 2010 — In a newly published article, the White House is advising physicians to accept a life in Big Medicine — as a hospital employee or member of a large group practice — in the wake of healthcare reform. Some leaders of organized medicine, however, are objecting to the government message. "We're not ready to write off the small practices," J. Fred Ralston Jr, MD, president of the American College of Physicians, told Medscape Medical News. "We think there needs to be more than one delivery model." "America is not a one-size-fits-all country," added M. Todd Williamson, MD, a neurologist from Lawrenceville, Georgia, and spokesperson for a coalition of medical societies opposed to the new healthcare reform law, now called the Affordable Care Act. Dr. Ralston and Dr.
閱讀完整內容

老美接受LTBI treatment的人，不到一半完治，和duration成正比

This study shows that although acceptance of LTBI treatment is relatively high (83%), the proportion completing is low (47%). When the product of these two proportions is calculated, we see that completion was achieved by only 39% of persons who were offered LTBI treatment. The major risk factor for noncompletion was being prescribed the 9-month INH regimen. As shown in Figure 1, when the proportions completing the three most commonly prescribed regimens are compared, it can be seen that there is an inverse relationship between length of the regimen prescribed and the proportion completing treatment. The increased completion that we observed with the 4-month rifampin regimen is consistent with previous reports.[18–20] It is of interest to note that if completion of the 9-month regimen were defined as completion of at least 6 months of INH, the noncompletion rate of the 9-month regimen, 42.9%, would have been almost identical to that of the 6-month regimen, 44.8%. Thus, prescribing the
閱讀完整內容